Regavirumab
Regavirumab is a human monoclonal antibody against infections with cytomegalovirus.[1]
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | cytomegalovirus glycoprotein B |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| KEGG | |
  | |
References
- Arizono, H; Sugano, T; Kaida, S; Shibusawa, K; Karasawa, Y; Esumi, Y; Kondo, S; Kiyoki, M (1994). "Pharmacokinetics of a new human monoclonal antibody against cytomegalovirus. Third communication: correspondence of the idiotype activity and virus neutralization activity of the new monoclonal antibody, regavirumab in rat serum and its pharmacokinetics in rats and monkeys". Arzneimittel-Forschung. 44 (7): 909–13. PMID 7945531.
This article is issued from
Wikipedia.
The text is licensed under Creative
Commons - Attribution - Sharealike.
Additional terms may apply for the media files.